Global Access to Multiple Myeloma Therapies.

IF 3 Q2 ONCOLOGY

JCO Global Oncology Pub Date : 2025-06-01 Epub Date: 2025-06-04 DOI:10.1200/GO-24-00441

Rawan Atallah, Yara Shatnawi, Md Fathima Shehnaz Ayoobkhan, Md Saiful Islam Saif, Menahil Naeem, Emerson Logan, Muhammad Umair Mushtaq, Shabeeha Rana, Aytaj Mammadzadeh, Shahrukh K Hashmi, Benlazar Mohamed, Nihar Desai, Thiago Xavier Carneiro, Rakesh Popat, Joseph P McGuirk, Shebli Atrash, Zahra Mahmoudjafari, Nada Hammad, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah

{"title":"Global Access to Multiple Myeloma Therapies.","authors":"Rawan Atallah, Yara Shatnawi, Md Fathima Shehnaz Ayoobkhan, Md Saiful Islam Saif, Menahil Naeem, Emerson Logan, Muhammad Umair Mushtaq, Shabeeha Rana, Aytaj Mammadzadeh, Shahrukh K Hashmi, Benlazar Mohamed, Nihar Desai, Thiago Xavier Carneiro, Rakesh Popat, Joseph P McGuirk, Shebli Atrash, Zahra Mahmoudjafari, Nada Hammad, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah","doi":"10.1200/GO-24-00441","DOIUrl":null,"url":null,"abstract":"Purpose: Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in the access to MM therapies worldwide, with a goal to investigate access to MM therapies and barriers globally.Methods: From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy/moderate access.Results: Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs.Conclusion: Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400441"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-24-00441","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in the access to MM therapies worldwide, with a goal to investigate access to MM therapies and barriers globally.

Methods: From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy/moderate access.

Results: Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs.

Conclusion: Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.

查看原文本刊更多论文

全球获得多发性骨髓瘤治疗。

目的：初步报告表明，目前在北美用于治疗多发性骨髓瘤（MM）的当代疗法的可及性在国际上有所不同。目前尚无研究定量报告全球MM治疗可及性的差异程度，目的是调查全球MM治疗可及性和障碍。方法：从2023年6月18日至7月15日，对176名在美国以外治疗MM的肿瘤学家进行电子调查。MM药物按可及性进行分类，60%的受访者确认容易/中等可及性。结果：来自33个国家的95名（54%）受访者完成了调查。51%的应答者来自大学的学术项目，17%的应答者只治疗浆细胞疾病。除了isatuximab， ixazomib， selinexor和elotuzumab外，大多数应答者都有足够的非细胞MM治疗途径。在细胞治疗中，17%的患者接受了嵌合抗原受体t细胞治疗，而23%的患者接受了批准的t细胞接合物（TCEs）治疗。患者和卫生保健系统面临的财务压力已成为全球无法获得治疗药物的主要障碍。结论：全球获得新型MM疗法仍然具有挑战性，我们已经确定了障碍并提出了弥补这一差距的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊